Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$127.75 USD

127.75
1,718,160

-1.59 (-1.23%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.69 -0.06 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Multiple Sclerosis is a Promising but Risky Space?

by Zacks Equity Research

Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.

    Kevin Cook headshot

    Bull of the Day: Regeneron (REGN)

    by Kevin Cook

    Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth

      Zacks Equity Research

      Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer

      by Zacks Equity Research

      Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).

        Zacks Equity Research

        PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y

        by Zacks Equity Research

        PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.

          Zacks Equity Research

          Are Alzheimer's-Focused Stocks Set for a Financial Windfall?

          by Zacks Equity Research

          Launch of the blood tests will help companies focused on developing preventive treatments make billions.

            Zacks Equity Research

            Biogen (BIIB) Down 17.2% Since Earnings Report: Can It Rebound?

            by Zacks Equity Research

            Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Zacks Equity Research

              What's in the Cards for Ionis (IONS) This Earnings Season?

              by Zacks Equity Research

              Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

                Zacks Equity Research

                Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

                by Zacks Equity Research

                Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

                  Zacks Equity Research

                  Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

                  by Zacks Equity Research

                  Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

                    Zacks Equity Research

                    FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

                    by Zacks Equity Research

                    FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

                      Zacks Equity Research

                      Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

                      by Zacks Equity Research

                      Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

                        Zacks Equity Research

                        Merck (MRK) Halts Another Late Stage Study on Alzheimer's

                        by Zacks Equity Research

                        Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

                            Zacks Equity Research

                            Biogen Halts Tysabri Development in Stroke as Study Fails

                            by Zacks Equity Research

                            Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

                              Zacks Equity Research

                              Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat

                              by Zacks Equity Research

                              Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

                                Zacks Equity Research

                                Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up

                                by Zacks Equity Research

                                Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

                                  Zacks Equity Research

                                  What's in the Cards for Biogen (BIIB) This Earnings Season?

                                  by Zacks Equity Research

                                  On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

                                    Zacks Equity Research

                                    Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

                                    by Zacks Equity Research

                                    Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

                                      Arpita Dutt headshot

                                      3 Pharma and Biotech Stocks to Watch Out for in 2018

                                      by Arpita Dutt

                                      Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

                                        Zacks Equity Research

                                        Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

                                        by Zacks Equity Research

                                        Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

                                          Zacks Equity Research

                                          Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs

                                          by Zacks Equity Research

                                          Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

                                            by Arpita Dutt

                                            Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                                              Zacks Equity Research

                                              Biogen's Alzheimer's Drug Misses Goal in Interim Analysis

                                              by Zacks Equity Research

                                              Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.

                                                Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                                  Zacks Equity Research

                                                  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

                                                  by Zacks Equity Research

                                                  Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.